Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Haleon PLC ( (GB:HLN) ) just unveiled an update.
Haleon PLC announced the purchase of 835,518 of its own ordinary shares as part of its share buyback program, which was initially announced in March 2025. This transaction reduces the number of shares with voting rights to 9,010,173,781, potentially impacting shareholder interests and market dynamics.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £4.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC’s overall stock score of 76 reflects its solid financial performance, strategic growth initiatives, and positive market sentiment. The company’s effective cash flow management and strategic focus on innovation and market expansion are significant strengths. However, caution is warranted due to valuation concerns and external challenges, such as currency fluctuations.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company’s product portfolio includes Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Haleon is known for its trusted brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Average Trading Volume: 27,611,571
Technical Sentiment Signal: Buy
Current Market Cap: £35.68B
For an in-depth examination of HLN stock, go to TipRanks’ Stock Analysis page.